Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update

Ensysce Biosciences, Inc. (NASDAQ:ENSC) saw a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 115,300 shares, a decrease of 97.6% from the November 15th total of 4,850,000 shares. Based on an average trading volume of 1,760,000 shares, the short-interest ratio is currently 0.1 days.

Institutional Investors Weigh In On Ensysce Biosciences

A hedge fund recently bought a new stake in Ensysce Biosciences stock. Anson Funds Management LP acquired a new stake in Ensysce Biosciences, Inc. (NASDAQ:ENSC) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 983,518 shares of the company’s stock, valued at approximately $236,000. Anson Funds Management LP owned 11.15% of Ensysce Biosciences as of its most recent filing with the Securities & Exchange Commission. 5.63% of the stock is currently owned by institutional investors.

Ensysce Biosciences Price Performance

ENSC stock traded down $0.04 during trading on Wednesday, reaching $6.81. 92,186 shares of the company were exchanged, compared to its average volume of 538,387. Ensysce Biosciences has a twelve month low of $2.12 and a twelve month high of $30.90. The company has a market capitalization of $8.89 million, a price-to-earnings ratio of -0.25 and a beta of 0.60. The company has a 50-day moving average of $6.77 and a two-hundred day moving average of $6.68.

Ensysce Biosciences (NASDAQ:ENSC) last posted its earnings results on Tuesday, November 12th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of ($4.50) by $5.55. Ensysce Biosciences had a negative return on equity of 292.81% and a negative net margin of 179.26%. The firm had revenue of $3.42 million during the quarter, compared to the consensus estimate of $0.25 million. On average, analysts forecast that Ensysce Biosciences will post -12.44 EPS for the current year.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.